Clinical trial · Observational
Ultrasound Radiomics for Predicting Breast Cancer and Axillary Lymph Node Metastasis
Accurate Prediction of Breast Cancer and Axillary Lymph Node Metastasis Burden by Multi-modal Ultrasound-based Radiomics
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The project is proposed based on multimodal ultrasonic imaging omics building used for accurate prediction of the breast cancer and axillary lymph node metastasis load artificial intelligence forecasting model, this method can dig the hidden features of ultrasonic image is not visible to the naked eye, make up the subjectivity in the process of clinical doctors in diagnosis and treatment, provide accurate, objective basis for clinical decision making.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Axillary Lymph Node Metastasis | Breast Neoplasm | PROBABILISTIC | 0.70 |
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Ultrasonic image analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- benign
- interventionNames
- Other: Ultrasonic image analysis
- label
- malignant
- interventionNames
- Other: Ultrasonic image analysis
Primary outcomes (1)
- measure
- Accuracy of differential diagnosis between benign and malignant
- timeFrame
- 2022.12.15-2023.12.30
- description
- ROC curve, sensitivity, specificity, accuracy, decision curve
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * patients who have not received breast puncture biopsy or neoadjuvant chemotherapy, etc. prior to ultrasonography; * patients who are not allergic to the ultrasound contrast agent (SonoVue) and have signed an informed consent form for ultrasonography * patients with breast tumors who have undergone surgical treatment at our hospital and have complete case histories. Exclusion Criteria: * patients with incomplete case data; * cases with large breast masses that do not completely show the region of interest (ROI); * patients who have undergone breast aspiration biopsy or other treatments such as neoadjuvant chemotherapy or endocrine therapy before ultrasound examination.
References
Publications (0)
Data not yet available